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Abstract
It was previously shown that carvedilol, a -adrenergic receptor antagonist
with antioxidant properties, was able to inhibit the mitochondrial permeabil-
ity transition (MPT). In the present work, the hypothesis was that the negative
impact of carvedilol on the MPT was specifically the result of its antioxidant
effect. For the current investigation, we used three different MPT inducers.
MPT-associated events were tested to study the protective effect of both
carvedilol and cyclosporin-A, the known MPT inhibitor. Carvedilol inhibited
mitochondrial swelling with calcium plus phosphate and with calcium plus
t-butylhydroperoxide, but not with calcium plus carboxyatractyloside. Car-
vedilol inhibited the oxidation of thiol groups with calcium plus phosphate
(p < 0.01) and with calcium plus t-butylhydroperoxide (p < 0.05), but not
with calcium plus carboxyatractyloside—in opposition to the full protection
afforded by cyclosporin-A when using calcium and carboxyatractyloside.
Our results showed that carvedilol was effective only when the MPT was
triggered by a primary oxidative process. This finding implies that the anti-
oxidant properties of carvedilol are crucial for the observed effects and rein-
forces the advantageous use of carvedilol in cardiac pathologies associated
with enhanced cellular oxidative stress.
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Introduction
The mitochondrial inner membrane permeability can increase owing to a cal-
cium-dependent phenomenon known as the mitochondrial permeability transition
(MPT), which is caused by the formation of pores of protein nature (mitochondrial
permeability transition pores [MPTP]). Agents like phosphate, pro-oxidant sys-
tems like t-butylhydroperoxide or xanthine oxidase plus hypoxanthine, and thiol
crosslinkers, such as phenylarsine oxide or carboxyatractyloside (a conformational
inhibitor of the adenine nucleotide translocator [ANT]), are known to decrease the
calcium threshold for MPT induction (1). During cardiac ischemia and reperfusion,
heart mitochondria suffer from increased oxidative injury and accumulation of
calcium and phosphate (2,3). MPT activation by oxidative stress and the protection
afforded by antioxidants has already been demonstrated in several studies (4–6).
The role of the MPT on myocyte reperfusion injury is well established and was
proposed to be determinant for the fate of the cardiac cell (7,8).
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